1-13 of 13
Carlos Caldas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkilä, Zena Wilson, Adina Hughes, Paul W.G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquin Arribas, Javier Cortés, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmaña, Mark J. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4536–4550.
https://doi.org/10.1158/1078-0432.CCR-22-0568
Published: 14 October 2022
View article titled, Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Open the PDF for Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View article titled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract A51: Personalized monitoring of treatment response using Targeted Digital Sequencing of circulating tumor DNA

Bradon R. McDonald, Tania Contente-Cuomo, Stephen-John Sammut, Michelle D. Stephens, Ahuva Odenheimer-Bergman, Brenda Ernst, Nieves Perdigones, Suet-Feung Chin, Maria Farooq, Rosa Mejia, Patricia A. Cronin, Karen S. Anderson, Heidi E. Kosiorek, Donald W. Northfelt, Ann E. McCullough, Bhavika K. Patel, Jeffrey N. Weitzel, Thomas P. Slavin, Carlos Caldas, Barbara A. Pockaj, Muhammed Murtaza
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A51.
https://doi.org/10.1158/1557-3265.LiqBiop20-A51
Published: 01 June 2020
View article titled, Abstract A51: Personalized monitoring of treatment response using Targeted Digital Sequencing of circulating tumor DNA
Journal Articles

BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer

Louise Walsh, Kathryn E. Haley, Bruce Moran, Brian Mooney, Finbarr Tarrant, Stephen F. Madden, Alessandra Di Grande, Yue Fan, Sudipto Das, Oscar M. Rueda, Catríona M. Dowling, Damir Varešlija, Suet-Feung Chin, Sabine Linn, Leonie S. Young, Karin Jirström, John P. Crown, Rene Bernards, Carlos Caldas, William M. Gallagher, Darran P. O'Connor, Tríona Ní Chonghaile
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (23): 7139–7150.
https://doi.org/10.1158/1078-0432.CCR-19-0713
Published: 02 December 2019
View article titled, BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Open the PDF for BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer in another window
Includes: Supplementary data
Journal Articles

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

Richard D. Baird, Annelot G.J. van Rossum, Mafalda Oliveira, Karin Beelen, Meiling Gao, Mariette Schrier, Ingrid A.M. Mandjes, Javier Garcia-Corbacho, Anne-Laure Vallier, Greig Dougall, Erik van Werkhoven, Constanza Linossi, Sanjeev Kumar, Harm van Tinteren, Maurizio Callari, Emma Beddowes, José-Manuel Perez-Garcia, Hilde Rosing, Else Platte, Petra Nederlof, Margaret Schot, Aurelia de Vries Schultink, René Bernards, Cristina Saura, William Gallagher, Javier Cortès, Carlos Caldas, Sabine C. Linn
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6598–6605.
https://doi.org/10.1158/1078-0432.CCR-19-0508
Published: 15 November 2019
View article titled, POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Open the PDF for POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy

Julian Puppe, Mark Opdam, Philip C. Schouten, Katarzyna Jóźwiak, Esther Lips, Tesa Severson, Marieke van de Ven, Chiara Brambillasca, Peter Bouwman, Olaf van Tellingen, René Bernards, Jelle Wesseling, Christian Eichler, Fabinshy Thangarajah, Wolfram Malter, Gaurav Kumar Pandey, Luka Ozretić, Carlos Caldas, Maarten van Lohuizen, Michael Hauptmann, Kerstin Rhiem, Eric Hahnen, H. Christian Reinhardt, Reinhard Büttner, Peter Mallmann, Birgid Schömig-Markiefka, Rita Schmutzler, Sabine Linn, Jos Jonkers
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4351–4362.
https://doi.org/10.1158/1078-0432.CCR-18-4024
Published: 15 July 2019
View article titled, EZH2 Is Overexpressed in <em>BRCA1</em>-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Open the PDF for EZH2 Is Overexpressed in <em>BRCA1</em>-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers

Violeta Serra, Cristina Cruz, Marta Castroviejo, Sara Gutiérrez, Alba Llop, Alejandra Bruna, Beatriz Morancho, Ginevra Caratú, Ludmila Prudkin, Ana Vivancos, Paolo Nuciforo, Mark O'Connor, Jos Jonkers, Carlos Caldas, Joaquin Arribas, José Baselga, Isabel T. Rubio, Cristina Saura, Orland Díez, Judith Balmaña, Javier Cortés
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B02.
https://doi.org/10.1158/1557-3265.PDX16-B02
Published: 15 August 2016
View article titled, Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers
Journal Articles

Abstract A7: Combined copy number and expression analysis of formalin fixed-paraffin embedded (FFPE) tumours

Mahesh Iddawela, Oscar Rueda, Yuker Wang, Malek Faham, Mohamed El-Sheemy, Ged Cowley, Jennifer Eremin, Oleg Eremin, Helena Earl, Carlos Caldas
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7_Supplement): A7.
https://doi.org/10.1158/1078-0432.TCME10-A7
Published: 02 February 2016
View article titled, Abstract A7: Combined copy number and expression analysis of formalin fixed-paraffin embedded (FFPE) tumours
Journal Articles

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Response

Qi Guo, Jean E. Abraham, Carlos Caldas, Helena M. Earl, Paul P.D. Pharoah
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 3094.
https://doi.org/10.1158/1078-0432.CCR-15-0944
Published: 30 June 2015
View article titled, Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Response
Open the PDF for Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Response in another window
Journal Articles

TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Børresen-Dale, Carlos Caldas, Anita Langerød
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (13): 3569–3580.
https://doi.org/10.1158/1078-0432.CCR-13-2943
Published: 30 June 2014
View article titled, <em>TP53</em> Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
Open the PDF for <em>TP53</em> Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance in another window
Includes: Supplementary data
Journal Articles

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

Jean E. Abraham, Qi Guo, Leila Dorling, Jonathan Tyrer, Susan Ingle, Richard Hardy, Anne-Laure Vallier, Louise Hiller, Russell Burns, Linda Jones, Sarah J. Bowden, Janet A. Dunn, Christopher J. Poole, Carlos Caldas, Paul P.D. Pharoah, Helena M. Earl
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (9): 2466–2475.
https://doi.org/10.1158/1078-0432.CCR-13-3232
Published: 30 April 2014
View article titled, Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
Open the PDF for Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel in another window
Includes: Supplementary data
Journal Articles

High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53

Abhi Veerakumarasivam, Helen E. Scott, Suet-Feung Chin, Anne Warren, Matthew J. Wallard, Donna Grimmer, Koichi Ichimura, Carlos Caldas, V. Peter Collins, David E. Neal, John D. Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2527–2534.
https://doi.org/10.1158/1078-0432.CCR-07-4129
Published: 01 May 2008
View article titled, High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies <em>Mouse Double Minute 4</em> (<em>MDM4</em>) as an Amplification Target Exclusive of <em>MDM2</em> and <em>TP53</em>
Open the PDF for High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies <em>Mouse Double Minute 4</em> (<em>MDM4</em>) as an Amplification Target Exclusive of <em>MDM2</em> and <em>TP53</em> in another window
Includes: Supplementary data
Journal Articles

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

Grace M. Callagy, Paul D. Pharoah, Sarah E. Pinder, Forrest D. Hsu, Torsten O. Nielsen, Joseph Ragaz, Ian O. Ellis, David Huntsman, Carlos Caldas
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (8): 2468–2475.
https://doi.org/10.1158/1078-0432.CCR-05-2719
Published: 25 April 2006
View article titled, Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index
Open the PDF for Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index in another window